JBM (Healthcare) Limited (HKG:2161)
Hong Kong · Delayed Price · Currency is HKD 2.780
+0.060 (2.21%)
At close: Feb 13, 2026
JBM (Healthcare) Income Statement
Financials in millions HKD. Fiscal year is April - March.
Millions HKD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 812.98 | 782.29 | 648.42 | 520.32 | 406.14 | 397.16 | |
Revenue Growth (YoY) | 12.83% | 20.65% | 24.62% | 28.12% | 2.26% | 4.09% |
Cost of Revenue | 351.56 | 368.59 | 310.33 | 314.81 | 244.63 | 198.73 |
Gross Profit | 461.42 | 413.71 | 338.08 | 205.51 | 161.51 | 198.43 |
Selling, General & Admin | 203.4 | 185.74 | 180.21 | 137.74 | 122.65 | 127.52 |
Other Operating Expenses | -7.34 | -5.61 | -4.37 | -2.71 | -2.44 | -2.46 |
Operating Expenses | 196.06 | 180.13 | 175.85 | 135.03 | 120.21 | 125.06 |
Operating Income | 265.36 | 233.58 | 162.24 | 70.48 | 41.31 | 73.37 |
Interest Expense | -5.57 | -4.46 | -8.5 | -8.21 | -6.41 | -7.41 |
Interest & Investment Income | 1.56 | 1.57 | 0.76 | 0.27 | 0.02 | 0.18 |
Earnings From Equity Investments | 0.72 | 0.07 | -0.82 | -1.93 | -1.79 | -1.19 |
Currency Exchange Gain (Loss) | 8.24 | 9.19 | 6.74 | 2.43 | 0.13 | -1.18 |
EBT Excluding Unusual Items | 270.32 | 239.94 | 160.43 | 63.03 | 33.26 | 63.77 |
Gain (Loss) on Sale of Investments | - | - | 4.47 | - | - | - |
Gain (Loss) on Sale of Assets | -0.13 | 0.9 | -0.01 | 8.77 | -0.01 | -0.2 |
Asset Writedown | - | - | - | - | -2.5 | - |
Other Unusual Items | 0.03 | 0.83 | - | 5.09 | - | -21.89 |
Pretax Income | 270.22 | 241.67 | 164.89 | 76.9 | 30.75 | 41.68 |
Income Tax Expense | 46.15 | 38.98 | 27.68 | 13.57 | 7.42 | 11.06 |
Earnings From Continuing Operations | 224.07 | 202.69 | 137.21 | 63.33 | 23.33 | 30.62 |
Minority Interest in Earnings | -7.68 | -5.43 | -6.75 | -6.24 | 1.29 | -8.02 |
Net Income | 216.39 | 197.26 | 130.46 | 57.09 | 24.62 | 22.6 |
Net Income to Common | 216.39 | 197.26 | 130.46 | 57.09 | 24.62 | 22.6 |
Net Income Growth | 32.04% | 51.20% | 128.51% | 131.90% | 8.94% | -44.91% |
Shares Outstanding (Basic) | 879 | 884 | 884 | 891 | 894 | 814 |
Shares Outstanding (Diluted) | 879 | 884 | 884 | 891 | 894 | 814 |
Shares Change (YoY) | 4.46% | - | -0.86% | -0.26% | 9.79% | 12.74% |
EPS (Basic) | 0.25 | 0.22 | 0.15 | 0.06 | 0.03 | 0.03 |
EPS (Diluted) | 0.25 | 0.22 | 0.15 | 0.06 | 0.03 | 0.03 |
EPS Growth | 26.41% | 51.20% | 130.48% | 132.92% | -0.95% | -51.13% |
Free Cash Flow | 158.66 | 205.92 | 181 | 137.48 | 52.94 | 35.8 |
Free Cash Flow Per Share | 0.18 | 0.23 | 0.20 | 0.15 | 0.06 | 0.04 |
Dividend Per Share | 0.212 | 0.170 | 0.075 | 0.030 | - | - |
Dividend Growth | 122.51% | 126.67% | 150.00% | - | - | - |
Gross Margin | 56.76% | 52.88% | 52.14% | 39.50% | 39.77% | 49.96% |
Operating Margin | 32.64% | 29.86% | 25.02% | 13.54% | 10.17% | 18.47% |
Profit Margin | 26.62% | 25.22% | 20.12% | 10.97% | 6.06% | 5.69% |
Free Cash Flow Margin | 19.52% | 26.32% | 27.91% | 26.42% | 13.03% | 9.01% |
EBITDA | 301.22 | 270.56 | 195.48 | 100.99 | 74.9 | 105.06 |
EBITDA Margin | 37.05% | 34.59% | 30.15% | 19.41% | 18.44% | 26.45% |
D&A For EBITDA | 35.86 | 36.98 | 33.24 | 30.52 | 33.6 | 31.69 |
EBIT | 265.36 | 233.58 | 162.24 | 70.48 | 41.31 | 73.37 |
EBIT Margin | 32.64% | 29.86% | 25.02% | 13.54% | 10.17% | 18.47% |
Effective Tax Rate | 17.08% | 16.13% | 16.79% | 17.65% | 24.12% | 26.54% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.